Cytokine Release Syndrome: all 163 studies

Page 2 of 2. Open to participants first (31), then studies with results posted, then the rest; newest registration first within each.

• UNITE Study (UMN-GE) for COVID-19CompletedNCT04701489Not applicable
• Expanded Access for Use of bmMSC-Derived Extracellular Vesicles in Patients With COVID-19 Associated ARDSNo longer availableNCT04657458
• Anakinra in the Management of COVID-19 InfectionCompletedNCT04643678Phase 2/3
• Anakinra, COVID-19, Cytokine StormWithdrawnNCT04603742Phase 2
• Cytokine Storm Among Bangladeshi Patients With COVID-19Status unknownNCT04598334
• Influence of Cytosorb on Amount of Catecholamine and Mortality in SepsisCompletedNCT04567199
• Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release SyndromeTerminatedNCT04540120Phase 2
• Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 PatientsStatus unknownNCT04517162Phase 1/2
• Investigational Treatments for COVID-19 in Tertiary Care Hospital of PakistanCompletedNCT04492501Not applicable
• Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19Status unknownNCT04486521
• Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm;CompletedNCT04485169Not applicable
• The Effect of Omega-3 on Selected Cytokines Involved in Cytokine StormCompletedNCT04483271Not applicable
• RAPA-501-Allo Therapy of COVID-19-ARDSTerminatedNCT04482699Phase 1/2
• Extracorporeal Blood Purification as a Treatment Modality for COVID-19CompletedNCT04478539
• The Effect of D3 on Selected Cytokines Involved in Cytokine Storm in the Covid-19 Uninfected Jordanian PeopleCompletedNCT04476745Not applicable
• Canakinumab MAP in COVID-19 Pneumonia With CRSNo longer availableNCT04476706
• Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 AdultsTerminatedNCT04475991Phase 2
• A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) PatientsTerminatedNCT04458298Phase 2
• Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19)Status unknownNCT04452942
• Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19Active, not recruitingNCT04433949Phase 3
• Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).TerminatedNCT04433546Phase 2
• RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORMWithdrawnNCT04433078Phase 2
• The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced PneumoniaStatus unknownNCT04422678Phase 3
• Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19TerminatedNCT04414631Phase 2
• Yoga Pranayama Adjuvant to Treat Burden COVID-19Status unknownNCT04413747Not applicable
• Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 DiseaseStatus unknownNCT04412395Phase 2
• Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory MarkersTerminatedNCT04403685Phase 3
• Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of OutcomeCompletedNCT04403061
• Ultra Low Doses of Therapy With Radiation Applicated to COVID-19SuspendedNCT04394182Not applicable
• Blood Ozonization in Patients With SARS-CoV-2 Respiratory FailureStatus unknownNCT04388514Not applicable
• Oral 25-hydroxyvitamin D3 and COVID-19Status unknownNCT04386850Phase 2/3
• Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane OxygenationSuspendedNCT04385771Not applicable
• CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19WithdrawnNCT04378244Phase 1/2
• The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary HyperinflammationStatus unknownNCT04377750Phase 4
• Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19TerminatedNCT04377503Phase 2
• MSCs in COVID-19 ARDSTerminatedNCT04371393Phase 3
• Colchicine in Patients With Mild and Severe Coronavirus DiseaseTerminatedNCT04367168Phase 2
• Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory SyndromeCompletedNCT04366908Phase 2
• Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 PatientsStatus unknownNCT04358627
• Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 InfectionNo longer availableNCT04355793
• Modulation of Hyperinflammation in COVID-19CompletedNCT04353674Not applicable
• Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19Status unknownNCT04351152Phase 3
• Safety and Efficacy of Ruxolitinib for COVID-19WithdrawnNCT04348071Phase 2/3
• Safety and Efficacy of Baricitinib for COVID-19WithdrawnNCT04340232Phase 2/3
• Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19TerminatedNCT04327505Phase 2/3
• Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane OxygenationCompletedNCT04324528Not applicable
• Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19Status unknownNCT04323228Phase 2/3
• Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19Status unknownNCT04306705
• Effect of Cytosorb on Blood Levels of Inflammatory Biomarkers of Sepsis.CompletedNCT04226430
• Early Haemadsorption in Major BurnsStatus unknownNCT04195126Not applicable
• Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T CellsStatus unknownNCT04082910Phase 1/2
• Cytokine Removal With CVVHD Compared to CVVHCompletedNCT04048525Not applicable
• Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS)Status unknownNCT04048434Not applicable
• Effects of Endotoxin Absorption and Cytokine Removal Hemofilter on Severe Septic ShockCompletedNCT03974386Not applicable
• Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary ResuscitationCompletedNCT03685383Not applicable
• Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel ImmunotherapiesTerminatedNCT03557749
• Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical TransplantationCompletedNCT03533101Phase 1/2
• Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALLActive, not recruitingNCT03016377Phase 1
• Blood Transfusions and Immune ResponseCompletedNCT02020525Not applicable
• Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)WithdrawnNCT02007239Phase 2
• Peri-operative Prediction of Prolonged Stay in the Cardiac Intensive Care Unit for Adult Cardiac SurgeryCompletedNCT01559870
• Study of the Clinical Scoring System and Cytokines for Prediction of Inflammatory Response in Major SurgeryCompletedNCT01353157
• Keratinocyte Growth Factor and Cytokines in Burns.CompletedNCT01302223

← Cytokine Release Syndrome overview